• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用暴露数据确定药物不良事件关系中的因果关系:以去甲文拉法辛为例。

Use of Exposure Data to Establish Causality in Drug-Adverse Event Relationships: An Example with Desvenlafaxine.

作者信息

Rodríguez-Lopez Andrea, Mejía-Abril Gina, Zubiaur Pablo, Calleja Sofía, Román Manuel, Abad-Santos Francisco, Ochoa Dolores

机构信息

Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.

出版信息

Pharmaceuticals (Basel). 2024 Jan 3;17(1):69. doi: 10.3390/ph17010069.

DOI:10.3390/ph17010069
PMID:38256902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10819155/
Abstract

Causality algorithms help establish relationships between drug use and adverse event (AE) occurrence. High drug exposure leads to a higher likelihood of an AE being classified as an adverse drug reaction (ADR). However, there is a knowledge gap regarding what concentrations are predictive of ADRs, as this has not been systematically studied. In this work, the Spanish Pharmacovigilance System (SEFV) algorithm was used to define the relationship between the AE occurrence and drug administration in 178 healthy volunteers participating in five desvenlafaxine single-dose clinical trials, a selective serotonin and norepinephrine reuptake inhibitor that may cause dizziness, headache, nausea, dry mouth, constipation and hyperhidrosis. Eighty-three subjects presented 172 AEs that were classified as possible (101), conditional (31), unrelated (24) and probable (16). AUC and C were significantly higher in volunteers with vs. without ADRs (5981.24 ng·h/mL and 239.06 ng/mL and 4770.84 ng·h/mL and 200.69 ng/mL, respectively). Six of 19 subjects with conditional AEs with an SEFV score of 3 points presented an AUC ≥ 6500 ng·h/mL or a C ≥ 300 ng/mL (i.e., above percentile 75) and were summed one point on their SEFV score and classified as "possible" (4 points), improving the capacity of ADR detection.

摘要

因果关系算法有助于确立药物使用与不良事件(AE)发生之间的关系。高药物暴露会使AE被归类为药物不良反应(ADR)的可能性更高。然而,关于何种浓度可预测ADR存在知识空白,因为尚未对此进行系统研究。在这项研究中,西班牙药物警戒系统(SEFV)算法被用于界定178名参与五项去甲文拉法辛单剂量临床试验的健康志愿者中AE发生与药物给药之间的关系,去甲文拉法辛是一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂,可能导致头晕、头痛、恶心、口干、便秘和多汗。83名受试者出现了172起AE,这些AE被分类为可能(101起)、条件性(31起)、不相关(24起)和很可能(16起)。发生ADR的志愿者与未发生ADR的志愿者相比,AUC和C显著更高(分别为5981.24 ng·h/mL和239.06 ng/mL以及4770.84 ng·h/mL和200.69 ng/mL)。19名条件性AE且SEFV评分为3分的受试者中有6名的AUC≥6500 ng·h/mL或C≥300 ng/mL(即高于第75百分位数),其SEFV评分加1分并被归类为“可能”(4分),提高了ADR检测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6b/10819155/361eae401572/pharmaceuticals-17-00069-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6b/10819155/361eae401572/pharmaceuticals-17-00069-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab6b/10819155/361eae401572/pharmaceuticals-17-00069-g001.jpg

相似文献

1
Use of Exposure Data to Establish Causality in Drug-Adverse Event Relationships: An Example with Desvenlafaxine.利用暴露数据确定药物不良事件关系中的因果关系:以去甲文拉法辛为例。
Pharmaceuticals (Basel). 2024 Jan 3;17(1):69. doi: 10.3390/ph17010069.
2
Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.帕罗西汀:在治疗惊恐障碍中的药理学和治疗潜力的综述。
CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.
3
Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers.揭示高脂餐对健康中国志愿者口服葡萄糖激酶激活剂曲格列汀药代动力学的影响。
Drugs R D. 2024 Mar;24(1):41-50. doi: 10.1007/s40268-023-00448-0. Epub 2023 Nov 20.
4
Monitoring drug safety in Astrakhan, Russia.俄罗斯阿斯特拉罕地区的药物安全监测。
Int J Risk Saf Med. 2015;27 Suppl 1:S33-4. doi: 10.3233/JRS-150680.
5
A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.一种在设计药物不良反应评估系统的概率评分系统中使用遗传算法的定量方法。
Int J Med Inform. 2008 Jun;77(6):421-30. doi: 10.1016/j.ijmedinf.2007.08.010. Epub 2007 Oct 24.
6
Impact of polymorphisms in and enzymes and and transporters on the pharmacokinetics and safety of desvenlafaxine.细胞色素P450酶和有机阴离子转运体中的多态性对去甲文拉法辛药代动力学和安全性的影响。
Front Pharmacol. 2023 Feb 2;14:1110460. doi: 10.3389/fphar.2023.1110460. eCollection 2023.
7
Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.2004 年至 2009 年向西班牙药物警戒系统报告的儿科药物不良反应。
Eur J Clin Pharmacol. 2012 Sep;68(9):1329-38. doi: 10.1007/s00228-012-1255-0. Epub 2012 Mar 14.
8
Serotonin and Norepinephrine Reuptake Inhibitors.5-羟色胺及去甲肾上腺素再摄取抑制剂
Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164.
9
[Analysis of reports of otoxicity, with symptoms of tinnitus, in the database of the Spanish Pharmacovigilance System for medicinal products for human use.].[对西班牙人用药品药物警戒系统数据库中有关耳毒性报告(伴有耳鸣症状)的分析。]
Rev Esp Salud Publica. 2020 Dec 9;94:e202012154.
10
A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020.一项关于2010年至2020年向药品不良反应监测中心报告的药品不良反应(ADR)的回顾性观察研究。
Curr Drug Saf. 2025;20(3):349-360. doi: 10.2174/0115748863317987241015034413.

本文引用的文献

1
Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.文拉法辛治疗抑郁症的治疗参考范围修订:系统评价和荟萃分析。
Psychopharmacology (Berl). 2024 Feb;241(2):275-289. doi: 10.1007/s00213-023-06484-7. Epub 2023 Oct 19.
2
Impact of polymorphisms in and enzymes and and transporters on the pharmacokinetics and safety of desvenlafaxine.细胞色素P450酶和有机阴离子转运体中的多态性对去甲文拉法辛药代动力学和安全性的影响。
Front Pharmacol. 2023 Feb 2;14:1110460. doi: 10.3389/fphar.2023.1110460. eCollection 2023.
3
Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors-A Population-Based Study in Spain.
药物不良反应和用药错误导致的紧急住院情况——西班牙一项基于人群的研究
Front Pharmacol. 2020 May 21;11:734. doi: 10.3389/fphar.2020.00734. eCollection 2020.
4
Adverse drug reactions.药物不良反应。
Med Clin (Barc). 2020 Mar 13;154(5):178-184. doi: 10.1016/j.medcli.2019.08.007. Epub 2019 Nov 23.
5
Venlafaxine pharmacogenetics: a comprehensive review.文拉法辛药物遗传学:全面综述。
Pharmacogenomics. 2019 Jul;20(11):829-845. doi: 10.2217/pgs-2019-0031. Epub 2019 Aug 1.
6
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.21 种抗抑郁药治疗成人重度抑郁症的急性治疗的疗效和可接受性比较:系统评价和网络荟萃分析。
Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.
7
[Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].[药品不良反应报告中的因果关系评估。西班牙药物警戒系统算法]
Med Clin (Barc). 2016 Nov 18;147(10):461-464. doi: 10.1016/j.medcli.2016.06.012. Epub 2016 Jul 20.
8
The importance of Good Clinical Practice guidelines and its role in clinical trials.《药物临床试验质量管理规范》指南的重要性及其在临床试验中的作用。
Biomed Imaging Interv J. 2008 Jan;4(1):e5. doi: 10.2349/biij.4.1.e5. Epub 2008 Jan 1.
9
Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.度洛西汀治疗重度抑郁症:基于证据的治疗地位综述
Core Evid. 2010 Jun 15;4:67-82. doi: 10.2147/ce.s5998.
10
The new European Medicines Agency guideline on the investigation of bioequivalence.新版欧洲药品管理局生物等效性研究指导原则
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):221-5. doi: 10.1111/j.1742-7843.2009.00518.x. Epub 2010 Jan 7.